What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict
FibroGen, Inc. (NASDAQ: FGEN) has a key catalyst Thursday when FDA's Cardiovascular and Renal Drugs Advisory Committee will issue its recommendation on the company's new drug application for roxadustat.
The committee is scheduled to meet between 9:30 a.m. and 5:30 p.m.
